BridgeBio's Navire preps SHP2 blocker for lung cancer trial after positive mouse study

AstraZeneca’s Tagrisso is effective in treating EGFR-mutated non-small cell lung cancer (NSCLC), but patients often become resistant to the drug over time. Researchers at the University of Texas MD Anderson Cancer Center and BridgeBio’s Navire Pharma developed a drug to block key resistance mechanisms, and now they’re headed to clinical trials backed by positive results in mice.